New cocktail aims to keep High-Risk myeloma at bay

NCT ID NCT05208307

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether a combination of belantamab mafodotin, pomalidomide, and dexamethasone can help prevent high-risk myeloma from returning after a stem cell transplant. About 34 patients who have already responded to transplant will receive the drug combo as maintenance therapy. The goal is to see how many achieve a complete response and how safe the treatment is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin, pomalidomide, and dexamethasone
What this could lead to: If successful, this combination could become a new maintenance option to help keep high-risk myeloma in remission longer after a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply to all patients. The drugs can cause side effects like eye problems, low blood counts, and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA

Contacts and locations

Locations

Emory University/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.